# A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes

Study · id `cardio:ct-nct07026968` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07026968](<https://clinicaltrials.gov/study/NCT07026968>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07026968

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 815 participants.

## Technical summary

Registry record NCT07026968. Randomized; double masking; primary purpose treatment. Start 2025-06-20 (actual); primary completion 2026-10-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 815 participants (planned count; ClinicalTrials.gov record NCT07026968, source copy `cardio:ctgov-nct07026968-2026-04-06`, retrieved 2026-10-26)
- Started: 2025-06-20 (actual) (ClinicalTrials.gov record NCT07026968, source copy `cardio:ctgov-nct07026968-2026-04-06`, retrieved 2026-10-26)
- Primary completion: 2026-10-30 (anticipated) (ClinicalTrials.gov record NCT07026968, source copy `cardio:ctgov-nct07026968-2026-04-06`, retrieved 2026-10-26)
- Completion: 2026-11-13 (anticipated) (ClinicalTrials.gov record NCT07026968, source copy `cardio:ctgov-nct07026968-2026-04-06`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07026968, source copy `cardio:ctgov-nct07026968-2026-04-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07026968-2026-04-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR
- Intervention (Drug): Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR
- Intervention (Drug): Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XR
- Intervention (Drug): Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XR
- Intervention (Drug): Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XR
- Lead sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: b17534c12d04b8458ed9409fce0f6b768fdbd9dda8ae665d9a87360957ff5efa
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
